Adenovirus vector vaccine as well as preparation method and application thereof
By mutating the negatively charged amino acids of the adenovirus hexon protein, changing its surface charge, solving the safety of adenovirus vectors, reducing the risk of thrombosis, improving the immune effect, and developing safe and efficient mucosal administration preparations to solve the problem of solving the problem of Safety and side effects of adenovirus vectors in application.
Patent Information
- Application Number
- CN202410698051.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-02
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
The existing adenovirus vectors have a risk of pre-existing immunity and replication capacity contamination in their applications, leading to side effects such as thrombosis, and their interaction with PF4 may cause thrombocytopenia and affect safety.
By mutating the negatively charged amino acids in the hexon protein of adenovirus are neutral or positively charged amino acids, the surface charge is changed, and the probability of interaction with PF4 is reduced, ensuring the safety and effectiveness of the adenovirus vector.
It reduces the probability of adenovirus causing thrombotic events, improves the immune effect, enhances the safety of vectors and the safety of gene therapy, provides a more efficient immunization method, and develops mucosal administration preparations to reduce local adverse reactions.
Smart Images

Figure CN119060965A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of vaccine technology, and in particular to a preparation method and application of an artificially modified adenovirus vector vaccine, and more particularly to a non-injectable adenovirus vector vaccine using a method for reducing the surface charge of an adenovirus vector. Background Art
[0002] Adenoviruses (Ads) are a large family of double-stranded DNA viruses with unencapsidated icosahedral capsid structures found in amphibians, birds, and mammals. Their good molecular genetic characterization makes adenovirus vectors a good candidate for use as vaccine carriers. The production of recombinant adenovirus vectors relies on the use of packaging cell lines that can complement the functions of adenovirus gene products. Adenoviruses are non-enveloped, icosahedral, and have 252 capsomers. Among them, the 20-faced vertices of the capsomers are 12 pentons, each penton has 2 fibers, and in addition to the pentons, there are 240 non-vertices, called hexons, with major genus and subgenus-specific antigenic determinants and minor species-specific antigenic determinants. The structural specificity of the hexon protein encodes neutralizing epitopes and participates in immune responses. So far, 101 adenoviruses have been isolated from the host.
[0003] Currently, two well-characterized human subgroup C adenovirus serotypes (i.e., hAd2 and hAd5) are widely used as the source of the viral backbone for most adenoviral vectors used for gene therapy. Replication-defective human adenoviral vectors have also been tested as vaccine vectors for the delivery of a variety of immunogens derived from a variety of infectious agents (e.g., viral, parasitic, or bacterial pathogens) and tumor cells, including tumor-associated antigens (TAAs). Two issues associated with the increasing use of replication-defective human adenoviral vectors are the risk of contamination with pre-existing immunity and the generation of replication-competent adenovirus (RCA).
[0004] In order to solve the above problems, the emergence of chimpanzee adenovirus vectors or other rare human serotypes of human adenovirus vectors provides a path, but the development of new types of adenovirus vectors has many safety issues. In the development of the new crown vaccine, AstraZeneca's vaccine uses chimpanzee ChAdOx1 adenovirus as a vector. The European Medicines Agency issued a statement saying that its subordinate Pharmacovigilance Risk Assessment Committee determined that abnormal thrombotic symptoms accompanied by thrombocytopenia should be listed as a very rare side effect of AstraZeneca's new crown vaccine. Later, an article published in Science Advances by a joint research team from Cardiff University in the UK and the United States revealed the mechanism by which the AstraZeneca vaccine may cause thrombosis. The British and American joint team believes that the culprit causing thrombosis is likely to be the interaction between the adenovirus vector ChAdOx1 used in the AstraZeneca vaccine and PF4 (platelet factor 4), which mistakenly triggers the immune system to release anti-PF4 antibodies and accumulate in the blood. PF4 is involved in the pathological mechanism of HIT (thrombocytopenia), which has clinical manifestations similar to those of TTS (thrombocytopenia syndrome). ChAdOx1 can also form a stable complex with PF4 and has high electronegativity. In a Brownian dynamics (BD) simulation, freely diffusing PF4 often contacts the capsid surface of ChAdOx1 between hexons, most commonly at the interface of three hexons. In contrast, Ad-26, another adenovirus vector used in the Johnson & Johnson COVID-19 vaccine, also forms contact with PF4, but at a lower frequency. This led the U.S. Centers for Disease Control and the Food and Drug Administration to recommend suspending the use of the vaccine. Research at the University of Nebraska Medical Center showed that the cause of thrombosis caused by the Johnson & Johnson COVID-19 vaccine is basically the same as that of the AstraZeneca COVID-19 vaccine.
[0005] Although adenovirus has been used for a long time, current research has not fully understood the risks of adenovirus, and adenovirus has unforeseen risks. Based on the problems of various types of adenovirus vectors, the inventors are committed to modifying adenovirus vectors to solve their safety issues. Summary of the invention
[0006] To achieve the above objectives, the inventors conducted a number of biological experiments on the modification of adenovirus, and through multiple experiments, clarified the modification method of adenovirus vectors, and provided a recombinant adenovirus and a modification method thereof.
[0007] Specifically provided is a recombinant adenovirus, wherein one or more negatively charged amino acids in the hexon protein of the adenovirus are mutated into neutral amino acids or positively charged amino acids.
[0008] The mutation region of the adenovirus hexon protein is the hypervariable region HVR of the adenovirus hexon protein;
[0009] The hypervariable region HVR of the adenovirus hexon protein includes one or more of HVR1, HVR2, HVR3, HVR4, HVR5, HVR6, and HVR7;
[0010] The negatively charged amino acids are aspartic acid and / or glutamic acid;
[0011] The neutral amino acid is selected from one or more of asparagine, glutamine, glycine, alanine, leucine, isoleucine, valine, cysteine, methionine, threonine, serine, and phenylalanine;
[0012] The neutral amino acid is selected from one or more of valine V, leucine L, asparagine N, glutamine Q, and isoleucine I;
[0013] The positively charged amino acid is selected from one or more of arginine R, lysine K, and histidine H;
[0014] The adenovirus hexon binds to PF4. The front and middle sections of the hexon have a large number of antigenic peaks and dense hydrophilic peaks. This region contains a large number of conserved regions with more hydrophobic amino acids. They become the key amino acids to maintain the spatial structural skeleton of the hexon and are very important for the formation of the secondary structure. The modification of adenovirus must be based on maintaining a reasonable structure, ensuring the basic functions of adenovirus, and solving the problem of interaction with PF4.
[0015] The recombinant adenovirus vector of the present invention can be used for gene therapy, tumor immunization and / or antiviral immunization. The recombinant adenovirus vector of the present invention can be used for gene delivery, and adenovirus particles can be specifically directed to target cells of interest, and the adenovirus binds to the specific target cells through capsid-receptor binding or other means and delivers the transgene.
[0016] The present invention also provides a composition comprising the recombinant adenovirus vector transformed by the above method.
[0017] The beneficial effects of the present invention include:
[0018] 1. The present invention provides a recombinant adenovirus, wherein the surface charge of the recombinant adenovirus is changed, which can reduce the probability of interaction with PF4, solve the safety problem of adenovirus, and reduce the probability of thrombotic events caused by adenovirus during use.
[0019] 2. In one aspect of the present invention, the recombinant adenovirus vector of the present invention is prepared into a vaccine vector for delivering various immunogens, and the immune effect is better than that of the existing commonly used adenovirus vectors.
[0020] 3. In one aspect of the present invention, the recombinant adenovirus vector of the present invention can be used for gene therapy, tumor immunization and / or antiviral immunization, and can be used for gene delivery. Adenovirus particles can be specifically directed to target cells of interest, and the adenovirus binds to the specific target cells through capsid-receptor binding or other means and delivers the transgene.
[0021] 4. In one aspect of the present invention, the composition prepared based on the recombinant adenovirus vector of the present invention has fewer side effects and higher safety in clinical applications.
[0022] 5. In one aspect of the present invention, the modified recombinant adenovirus can be used to develop a mucosal administration preparation, for example, by inhalation, to simulate the virus infection process and stimulate an immune response. Local adverse reactions such as pain at the injection site caused by intramuscular injection can be avoided. By inhaling into the lungs, the atomized vaccine can pass through the respiratory tract and finally reach the lungs, stimulating respiratory mucosal immunity while producing humoral immunity and cellular immunity. The mucosal administration preparation of the present invention is not only more compliant than injection, but also has a lower dosage, and can also produce a triple protection effect of humoral immunity, cellular immunity and mucosal immunity. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 Surface charge of chimpanzee adenovirus vector ChAdOx1 with different HVR mutations
[0024] Figure 2 .Titers of chimpanzee adenovirus vector ChAdOx1 with different HVR mutations
[0025] Figure 3 .Surface charge of combined mutations in HVR2 and HVR7 regions of chimpanzee adenovirus vector ChAdOx1
[0026] Figure 4 .Titer of chimpanzee adenovirus vector ChAdOx1 combined mutation of HVR2 and HVR7 regions
[0027] Figure 5 .Combined mutations in HVR2 and HVR7 regions of chimpanzee adenovirus vector ChAdOx1 (different neutral amino acids) Surface charge
[0028] Figure 6 . Virus titer of chimpanzee adenovirus vector ChAdOx1 HVR2 and HVR7 combined mutations (different neutral amino acids)
[0029] Figure 7 .Surface charge of chimpanzee adenovirus vector ChAdOx1 HVR1 / 2 / 5 / 7 combined mutations
[0030] Figure 8. Chimpanzee adenovirus vector ChAdOx1 HVR1 / 2 / 5 / 7 combined mutant virus titer DETAILED DESCRIPTION
[0031] Unless otherwise defined, all scientific and technical terms used in the present invention have the same meanings as commonly understood by one of ordinary skill in the art to which the present invention relates.
[0032] The term "recombinant" as used herein implies that it has been artificially modified, ie, it is not a naturally occurring wild-type adenovirus.
[0033] The term "recombinant adenovirus" as used herein is based on an adenovirus as used herein, derived at least in sequence from the wild type. This can be achieved by using the wild type genome or a portion thereof as starting material for molecular cloning. The known sequence of the wild type adenovirus genome can also be used to regenerate (a portion of) the genome by DNA synthesis, which can be performed by commercial service companies in the field of DNA synthesis and / or molecular cloning (e.g., GeneArt, Invitrogen, GenScripts, Eurofins) using conventional procedures.
[0034] As used herein, the term "fragment" refers to an amino-terminal and / or carboxyl-terminal and / or internal deletion, and it should be understood that for the purpose of inducing an immune response and generally for vaccination, the protein does not need to be full-length, nor does it need to have all of its wild-type functions, and fragments of the protein are equally applicable.
[0035] The term "composition" as used herein refers to a vaccine or other composition prepared using a recombinant adenovirus that can express the target gene and uses adenovirus as a vector to recombinantly integrate the target gene into the adenovirus genome.
[0036] As is conventional in the art, sequences herein are provided in the 5' to 3' direction.
[0037] A recombinant adenovirus, wherein one or more negatively charged amino acids in the hexon protein of the adenovirus are mutated into neutral amino acids or positively charged amino acids. The mutated region of the hexon protein is the hypervariable region HVR of the adenovirus hexon protein, including one or more of HVR1, HVR2, HVR3, HVR4, HVR5, HVR6, and HVR7; the mutated region of the hypervariable region HVR of the hexon protein includes at least HVR2 and HVR7.
[0038] The negatively charged amino acids are aspartic acid and / or glutamic acid;
[0039] The neutral amino acid is selected from one or more of asparagine, glutamine, glycine, alanine, leucine, isoleucine, valine, cysteine, methionine, threonine, serine, and phenylalanine, preferably one or more of valine, leucine, asparagine, and glutamine.
[0040] The positively charged amino acid is selected from one or more of arginine, lysine and histidine.
[0041] At least one negatively charged amino acid in the hypervariable region HVR is mutated to a neutral amino acid.
[0042] The mutation regions of the adenovirus hexon protein are: D144 and / or E159 of HVR1 or their equivalent positions; D171 and / or D175 and / or D177 of HVR2 or their equivalent positions; D265 of HVR5 or their equivalent positions; and / or D423 and / or D425 and / or E427 and / or E429 of HVR7 or their equivalent positions.
[0043] The adenovirus referred to includes: simian adenovirus or human adenovirus.
[0044] The adenovirus comprises any one of the seven subgroups A, B, C, D, E, F, and G of simian adenovirus, such as sAd1, sAd10, sAd11, sAd12, sAd13, sAd14, sAd15, sAd16, sAd18, sAd19, sAd2, sAd20, sAd23, sAd25, sAd26, sAd27, sAd28, sAd29, sAd3, sAd30, sAd31, sAd32, sAd33, sAd34, sAd35, sAd37, sAd38, sAd39, sAd4, sAd40, sAd43, sAd44, sAd 45, sAd46, sAd47, sAd48, sAd49, sAd6, sAd9, AdY25, AdC8, AdC22, AdC30, AdC37, AdC11, AdC3, AdC17, AdC19, AdC31, AdC20, AdC24, AdC16, Ad C26,AdC82,AdC5,AdC7,AdC44,AdC38,AdC43,AdC63,AdC147,AdC73,AdC6,AdC55,AdC83,AdC143,AdC144,AdC145,AdC10,AdC28,AdC9,AdC6
[0045] Any of the seven subgroups A, B, C, D, E, F, and G of Rhesus adenovirus, such as RhAd51, RhAd52, RhAd53, RhAd54, RhAd55, RhAd56, RhAd57, RhAd58, RhAd59, RhAd60, RhAd61, RhAd62, RhAd63, RhAd64, RhAd65, RhAd66, RhAd67, CyAd1
[0046] Any of the seven subgroups A, B, C, D, E, F, and G of Gorilla adenovirus, such as GoAd B20, GoAdB22, GoAd B21, GoAd B10, GoAd B11, GoAd B12, GoAd B13, GoAd B14, GoAd B19, GoAd E1, GoAd C10, GoAd C11, GoAd C12, GoAd C13, GoAd C14, GoAd C15, GoAd C16, GoAd C17, GoAdC18, GoAd1, and GoAd 2;
[0047] Any of the seven subgroups A, B, C, D, E, F, and G of baboon adenovirus, such as BaAd 3;
[0048] Any one of the seven subgroups A, B, C, D, E, F, and G of human adenovirus, such as: Ad1, Ad10, Ad11, Ad12, Ad14, Ad15, Ad17, Ad18, Ad19, Ad2, Ad20, Ad21, Ad22, Ad23, Ad25, Ad26, Ad27, Ad28, Ad29, Ad3, Ad30, Ad31, Ad32, Ad33, Ad34, Ad35, Ad36, Ad38, Ad39, Ad4, Ad40, Ad41, and Ad42 , Ad43, Ad44, Ad45, Ad46, Ad47, Ad48, Ad49, Ad5, Ad50, Ad51, Ad52, Ad53, Ad54, Ad55, Ad56, Ad57, Ad6, Ad60, Ad61, Ad62, Ad63, Ad64, Ad65, Ad66, Ad68, Ad7, Ad89, Ad81, Ad86, Ad8E, AdD8AdD9, AdD37, AdD10, AdD13, AdD110, AdD109
[0049] The method for preparing a recombinant adenovirus comprises introducing the recombinant adenovirus into complementary cells, culturing the cells and harvesting the virus.
[0050] Uses of recombinant adenovirus include gene therapy, tumor immunization and / or antiviral immunization.
[0051] The use of recombinant adenovirus includes inducing primary immune response in humans or mammals, inducing booster immune response, and destroying host tolerance to self-antigens.
[0052] A composition comprises the recombinant adenovirus and at least one heterologous transgene. The heterologous transgene carries a viral or bacterial antigen. The viral or bacterial antigen is selected from the group consisting of HIV, rabies virus, dengue virus, Ebola virus, coronavirus, human papillomavirus, hepatitis C virus, hepatitis B virus, rotavirus, measles virus, respiratory syncytial virus (RSV), herpes zoster virus (VZV), cytomegalovirus, herpes simplex virus type 2, Epstein-Barr virus, human metapneumovirus, parainfluenza virus, influenza virus, Trypanosoma cruzi and Plasmodium falciparum, Mycobacterium tuberculosis, Streptococcus pneumoniae, Moraxella catarrhalis, NTHi hemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Staphylococcus aureus, Helicobacter pylori, and Chlamydia trachomatis.
[0053] The composition includes pharmaceutically acceptable excipients, such as one or more of a buffer, a protective agent, a stabilizer, a surfactant, an osmotic pressure regulator, an adjuvant, a preservative, and an inactivator. The buffer includes one or more of HEPES, HIS, TRIS, PB, succinic acid, and citric acid; the protective agent includes one or more of gelatin, ethanol, diethylaminotetraacetic acid (EDTA), disodium diethylaminotetraacetic acid (EDTA-2Na), and magnesium chloride; the stabilizer includes one or more of sucrose, mannitol, fucose, and maltose; the surfactant includes one or more of Tween, Span, and glycerol; the osmotic pressure regulator includes sodium chloride or is omitted; the excipient components include one or more of mannitol, sucrose, sodium chloride, magnesium chloride, HEPES, polysorbate 80, and glycerol.
[0054] The composition can be prepared as a mucosal immune preparation, a humoral immune preparation, a cellular immune preparation, or a skin immune preparation. The mucosal immune preparation is a liquid dosage form, a solid dosage form, a semisolid dosage form, a gas dosage form, or an inhalation dosage form. The composition can be administered by intravenous injection, intramuscular injection, subcutaneous injection, oral administration, oral administration, sublingual administration, rectal administration, respiratory administration, and transdermal administration. The administration method, respiratory administration is oral inhalation, nasal inhalation, or inhalation after atomization by an atomizer. The composition, the unit dose is 0.05-5ml, preferably, 0.1-1ml.
[0055] The uses of the composition include use in medicine, use in delivering transgenes into host cells, use in eliciting a primary immune response in humans or animals to treat or prevent at least one disease, use in enhancing the immune response in humans or animals, and use in inducing an immune response in humans or animals to break tolerance to self-antigens.
[0056] The method for producing the composition comprises providing nucleic acid of a protein or a fragment thereof of a heterologous gene, allowing the recombinant adenovirus to proliferate in a host cell, isolating and purifying the recombinant adenovirus, and formulating the recombinant adenovirus into a pharmaceutically acceptable composition.
[0057] To further verify the efficacy of the present invention, a recombinant chimpanzee adenovirus ChAdOx1 (SEQ.NO.1) is provided in certain embodiments, wherein one or more negatively charged amino acids in the hexon protein of the ChAdOx1 adenovirus are mutated into neutral amino acids or positively charged amino acids. The mutations of the negatively charged amino acids in the hexon protein of the recombinant chimpanzee adenovirus ChAdOx1 are specifically: SEQ.NO.2-SEQ.NO.15
[0058]
[0059] The hypervariable region HVR of the hexon protein includes one or more negatively charged amino acids in HVR1, HVR2, HVR5, and HVR7 mutated into neutral amino acids or positively charged amino acids.
[0060] The negatively charged amino acids of the hexon protein of the recombinant chimpanzee adenovirus ChAdOx1 are D144 and / or E159 of HVR1; the negatively charged amino acids of the hexon protein are D171 and / or D175 and / or D177 of HVR2; the negatively charged amino acids of the hexon protein are D265 of HVR5; the negatively charged amino acids of the hexon protein are D423 and / or D425 and / or E427 and / or E429 of HVR7;
[0061] The neutral amino acid after the negatively charged amino acid mutation of the recombinant chimpanzee adenovirus ChAdOx1 hexon protein is one or more of valine, leucine, asparagine and glutamine. The positively charged amino acid is one or more of arginine R, lysine K and histidine H.
[0062] The mutation region of the hypervariable region HVR of the hexon protein includes at least HVR2 and HVR7. In certain embodiments, the mutation of the negatively charged amino acid of the recombinant chimpanzee adenovirus ChAdOx1 hexon protein is specifically: SEQ.NO.16-SEQ.NO.38
[0063]
[0064] In certain embodiments, a recombinant chimpanzee adenovirus ChAdOx1 is provided, wherein the hypervariable region HVR of the hexon protein of the ChAdOx1 adenovirus includes one or more negatively charged amino acids in HVR1, HVR2, HVR5, and HVR7 mutated to positively charged amino acids, SEQ.NO.18-SEQ.NO.30.
[0065]
[0066]
[0067] In certain embodiments, a recombinant chimpanzee adenovirus ChAdOx1 is provided, wherein the mutation region of the hexon protein of the ChAdOx1 adenovirus includes hypervariable regions HVR1, HVR2 and HVR7 (SEQ.NO.39), HVR2, HVR5 and HVR7 (SEQ.NO.40) or HVR1HVR7, HVR2, HVR5 and HVR7 (SEQ.NO.41-SEQ.NO.50).
[0068]
[0069] In certain embodiments, the collected adenovirus is further purified. Adenovirus purification can be performed in several steps, including purification, ultrafiltration, diafiltration, or chromatographic separation. Purification can be performed by a filtration step to remove cell debris and other impurities from the cell lysate. Ultrafiltration is used to concentrate the virus solution. Diafiltration or buffer exchange using an ultrafilter is a way to remove and exchange salts, sugars, and the like. It is known to those of ordinary skill how to find the optimal conditions for each purification step.
[0070] A composition comprises the recombinant chimpanzee adenovirus vector transformed by the above method.
[0071] Specifically, the viral or bacterial antigens encapsulated by the above-mentioned transgene are selected from: HIV, rabies virus, dengue virus, Ebola virus, coronavirus, human papillomavirus, hepatitis C virus, hepatitis B virus, rotavirus, measles virus, respiratory syncytial virus (RSV), herpes zoster virus (VZV), cytomegalovirus, herpes simplex virus type 2, Epstein-Barr virus, human metapneumovirus, parainfluenza virus, influenza virus, Trypanosoma cruzi and Plasmodium falciparum, Mycobacterium tuberculosis, Streptococcus pneumoniae, Moraxella catarrhalis, NTHi hemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Staphylococcus aureus, Helicobacter pylori, Chlamydia trachomatis or one or more.
[0072] The composition of the present invention includes pharmaceutically acceptable excipients, such as one or more of a buffer, a protective agent, a stabilizer, a surfactant, an osmotic pressure regulator, an adjuvant, a preservative, and an inactivator. The buffer includes one or more of HEPES, HIS, TRIS, PB, succinic acid, and citric acid; the protective agent includes one or more of gelatin, ethanol, diethylaminotetraacetic acid (EDTA), disodium diethylaminotetraacetic acid (EDTA-2Na), and magnesium chloride; the stabilizer includes one or more of sucrose, mannitol, fucose, and maltose; the surfactant includes one or more of Tween, Span, and glycerol; the osmotic pressure regulator includes sodium chloride or is omitted; the excipient components include one or more of mannitol, sucrose, sodium chloride, magnesium chloride, HEPES, polysorbate 80, and glycerol.
[0073] The composition of the present invention can be prepared into a mucosal immune preparation, a humoral immune preparation, a cellular immune preparation, or a skin immune preparation. The mucosal immune preparation is in the form of a liquid dosage form, a solid dosage form, a semisolid dosage form, a gas dosage form, or an inhalation dosage form.
[0074] The composition of the present invention can be administered by intravenous injection, intramuscular injection, subcutaneous injection, oral administration, buccal administration, sublingual administration, rectal administration, respiratory tract administration, and transdermal administration. Respiratory tract administration is inhalation through the mouth, inhalation through the nose, or inhalation after atomization by an atomizing device.
[0075] The composition of the present invention has a unit dose of 0.05-5 ml, preferably 0.1-1 ml.
[0076] The uses of the composition of the present invention include use in medicine, use in delivering transgenes into host cells, use in eliciting a primary immune response in humans or animals to treat or prevent at least one disease, use in enhancing the immune response in humans or animals, and use in inducing an immune response in humans or animals that breaks tolerance to self-antigens.
[0077] The method for making the composition comprises providing nucleic acid of a protein or a fragment thereof of a heterologous gene, propagating the replication-deficient chimpanzee recombinant adenovirus in a host cell, isolating and purifying the recombinant adenovirus, and formulating the recombinant adenovirus into a pharmaceutically acceptable composition.
[0078] As used herein, the subject is preferably a mammal, such as a rodent, such as a mouse, a cotton rat, or a non-human primate, or a human. The subject is preferably a human subject. The subject can be of any age, such as from about 1 month old to 100 years old, such as from about 2 months old to about 80 years old, such as from about 1 month old to about 3 years old, from about 3 years old to about 50 years old, from about 50 years old to about 75 years old, etc.
[0079] The method for further constructing a recombinant adenovirus containing a virus or bacterial antigen by the recombinant adenovirus of the present invention includes: using a reverse genetic method, using MssI to remove ori, resistance genes and other elements that do not belong to the viral genome, and linearizing the plasmid at the same time, using a commercial purification and recovery kit to purify the linearized plasmid, removing the enzyme and other reaction components therein, taking 1-2ug of the purified linear plasmid and using a lipo2000 kit to transfect HEK293SF-3F6 cells grown in a 6-well plate, and transferring to a T25 bottle for culture the next day to remove the lipo2000 reagent that is harmful to the cells, and at the same time allowing the cells to have a larger growth space. After 7 days, the empty plaques produced by the poisoning can be observed, and the cells at the empty plaques fall off to form cavities.
[0080] The method for further constructing a recombinant adenovirus containing a viral or bacterial antigen also includes optimizing the viral or bacterial antigen gene, performing a PCR experiment and recovering the product by enzyme digestion, and recovering the enzyme digestion fragment. At the same time, the plasmid vector is digested with the same nuclease to recover the recombinant vector; the vector and the backbone plasmid are co-transfected into HEK293SF-3F6 cells for virus rescue. After 10-20 days, plaques produced by virus release can be observed, and cells at the plaques fall off to form cavities.
[0081] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0082] Example 1 Chimpanzee adenovirus vector ChAdOx1-HVR mutation (different HVR region mutation regions)
[0083] Based on the chimpanzee ChAdOx1 adenovirus vector, the following mutations were performed to study the charge effects of different HVR mutation regions on adenovirus titer and virus purification.
[0084] Table 1. Mutations in different HVR regions of chimpanzee adenovirus vector ChAdOx1
[0085]
[0086] according to Figure 1 The experimental results showed that compared with the wild-type chimpanzee adenovirus ChAdOx1, the negative charge of ChAdOx1-Hexon_HVRmutation strategy 5 and ChAdOx1-Hexon_HVR mutation strategy 9 was reduced.
[0087] The virus titer results showed that the wild-type ChAdOx1 virus in group 1 had the highest titer, followed by groups 5 and 9-ChAdOx1-Hexon_HVR mutation strategy 5 and 9.
[0088] Example 2 Chimpanzee adenovirus vector ChAdOx1-HVR mutation (HVR region combined mutation)
[0089] Based on the chimpanzee ChAdOx1 adenovirus vector, the following mutations were performed to study the charge effects of combined mutations in the HVR2 and HVR7 regions on adenovirus titer and virus purification.
[0090] Table 2. Combined mutations in the HVR2 and HVR7 regions of chimpanzee adenovirus vector ChAdOx1
[0091]
[0092]
[0093] according to Figure 3 The experimental results showed that compared with the wild-type chimpanzee adenovirus ChAdOx1, the negative charge on the surface of the adenovirus in group 1-15-ChAdOx1-Hexon_HVR mutation strategy 16-30 was reduced.
[0094] Figure 4 The virus titer results showed that group 2-ChAdOx1-Hexon_HVR mutation strategy 17 had the lowest virus titer.
[0095] Example 3 Chimpanzee adenovirus vector ChAdOx1-HVR mutation (different neutral amino acid combination mutations in HVR2 and HVR 7)
[0096] Based on the chimpanzee ChAdOx1 adenovirus vector, the following mutations were performed to study the charge effects of mutations in the HVR2 and HVR7 regions to different neutral amino acids on adenovirus titer and virus purification.
[0097] Table 3. Combination mutations in the HVR2 and HVR7 regions of chimpanzee adenovirus vector ChAdOx1 (different neutral amino acids)
[0098]
[0099] according to Figure 5 The experimental results showed that compared with the wild-type chimpanzee adenovirus ChAdOx1, the negative charge on the surface of group 1-9-ChAdOx1-Hexon_HVR mutation strategy 31-38 adenovirus was reduced.
[0100] Figure 6 The virus titer results showed that group 1-9-ChAdOx1-Hexon_HVR mutation strategy was basically the same as the wild-type ChAdOx1 (Example Group 1), and the replication was normal.
[0101] Example 4 Chimpanzee adenovirus vector ChAdOx1-HVR mutation (HVR2 and 7 combined with HVR1 and HVR5)
[0102] Based on the chimpanzee ChAdOx1 adenovirus vector, the following mutations were performed to study the effects of other combined mutations on adenovirus titer, charge during virus purification, and interaction with PF4 based on the HVR2 and HVR7 regions.
[0103] Table 4. Chimpanzee adenovirus vector ChAdOx1 HVR1 / 2 / 5 / 7 combined mutations
[0104]
[0105] according to Figure 7 The experimental results showed that compared with the wild-type chimpanzee adenovirus ChAdOx1, the negative charge on the surface of the adenovirus in group 1-12-ChAdOx1-Hexon_HVR mutation strategy 39-50 was reduced.
[0106] PF4 interaction experiment results Figure 8 It showed that the dissociation constant between ChAdOx1-Hexon_HVR mutation strategy39-50 and PF4 increased, indicating that its interaction with PF4 was reduced.
Claims
1. A recombinant adenovirus, characterized in that: One or more negatively charged amino acids in the hypervariable region HVR of the hexon protein of the adenovirus are mutated into neutral amino acids and / or positively charged amino acids.
2. The recombinant adenovirus according to claim 1, characterized in that The hypervariable region HVR of the hexon protein includes one or more of HVR1, HVR2, HVR3, HVR4, HVR5, HVR6, and HVR7.
3. The recombinant adenovirus according to claim 1 or 2, characterized in that: The mutation region of the hypervariable region HVR of the hexon protein at least includes HVR2 and / or HVR7.
4. The recombinant adenovirus according to any one of claims 1 to 3, characterized in that The negatively charged amino acid is aspartic acid D and / or glutamic acid E. The neutral amino acid is selected from one or more of valine V, leucine L, asparagine N, glutamine Q, and isoleucine I; and the positively charged amino acid is selected from one or more of arginine R, lysine K, and histidine H.
5. The recombinant adenovirus according to any one of claims 1 to 4, characterized in that At least one negatively charged amino acid in the hypervariable region HVR is mutated to a neutral amino acid.
6. The recombinant adenovirus according to any one of claims 1 to 5, characterized in that The mutation regions of the adenovirus hexon protein are: D144 and / or E159 of HVR1 or their equivalent positions; D171 and / or D175 and / or D177 of HVR2 or their equivalent positions; D265 of HVR5 or their equivalent positions; and / or D423 and / or D425 and / or E427 and / or E429 of HVR7 or their equivalent positions.
7. A method for producing the recombinant adenovirus according to any one of claims 1 to 6, characterized in that: The method comprises introducing the recombinant adenovirus into complementary cells, culturing the cells and harvesting the virus.
8. Use of the recombinant adenovirus according to any one of claims 1 to 6 in the preparation of a medicament, characterized in that: These include gene therapy, tumor immunization, and / or antiviral immunization.
9. Use of the recombinant adenovirus according to any one of claims 1 to 6 in the preparation of a medicament, characterized in that: The invention includes the use of eliciting a primary immune response in humans or mammals, eliciting a booster immune response or for destroying host tolerance to self-antigens.
10. A composition, characterized in that The method comprises the recombinant adenovirus according to any one of claims 1 to 6, and at least one heterologous transgene, wherein the heterologous transgene carries a viral or bacterial antigen.
11. A composition according to claim 10, characterized in that The viral or bacterial antigens are selected from: HIV, rabies virus, dengue virus, Ebola virus, coronavirus, human papillomavirus, hepatitis C virus, hepatitis B virus, rotavirus, measles virus, respiratory syncytial virus (RSV), herpes zoster virus (VZV), cytomegalovirus, herpes simplex virus type 2, Epstein-Barr virus, human metapneumovirus, parainfluenza virus, influenza virus, Trypanosoma cruzi and Plasmodium falciparum, Mycobacterium tuberculosis, Streptococcus pneumoniae, Moraxella catarrhalis, NTHi hemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Staphylococcus aureus, Helicobacter pylori, Chlamydia trachomatis or one or more.
12. The composition according to any one of claims 10 to 11, characterized in that It includes pharmaceutically acceptable excipients. Preferably, the pharmaceutically acceptable excipients are selected from one or more of a buffer, a protective agent, a stabilizer, a surfactant, an osmotic pressure regulator, an adjuvant, a preservative, and an inactivator.
13. The composition according to any one of claims 10 to 11, characterized in that The composition is a mucosal immune preparation, a humoral immune preparation, a cellular immune preparation, and a skin immune preparation.
14. The composition according to any one of claims 13, characterized in that Mucosal immunotherapy preparations are in the form of liquid, solid, semisolid, gas, and inhaled dosage forms.
15. A composition according to any one of claims 10-11, characterized in that The composition is a drug administration preparation. Preferably, the drug administration preparation is an intravenous injection, an intramuscular injection, a subcutaneous injection, an oral administration preparation, a buccal administration preparation, a sublingual administration preparation, a rectal administration preparation, a respiratory administration preparation, or a transdermal administration preparation; preferably, it is a respiratory administration preparation, which is an oral inhalation, a nasal inhalation, or an inhalation preparation after atomization by an atomization drug administration device.
16. Use of the composition according to any one of claims 10 to 15 in the preparation of a medicament, characterized in that: The medicament is used for one or more of the following purposes: gene therapy, tumor vaccination, antiviral vaccination, delivery of transgenes into host cells, for eliciting a primary immune response in humans or animals, for boosting an immune response in humans or animals, and for inducing an immune response in humans or animals that breaks tolerance to self-antigens.
17. A method for producing the composition according to any one of claims 10 to 15, characterized in that The invention comprises a nucleic acid providing a protein or a fragment thereof of a heterologous gene, allowing the recombinant adenovirus to proliferate in a host cell, isolating and purifying the recombinant adenovirus, and formulating the recombinant adenovirus into a pharmaceutically acceptable composition.
